Dr Ian Smith (Co-founder, Director and Chief Medical Officer) and Chris Dodd (Chief Commercial Officer) recently spoke to Jo Shorthouse at In Vivo to discuss the practicalities and reality of running clinical trial sites as a business, the efficiencies found with the SMO model, the challenge of patient recruitment as well as the decentralized and hybridized trial model. To listen to the …
The independent Site Management Organisations (SMOs) which run clinical trials on behalf of the pharmaceutical industry continue to expand not only the number of trials being brought to the UK but also the number of patients enrolled.
New data show that the site management model reduces start-up times for a Phase II or Phase III clinical trial by up to nine months compared to UK public sites, representing billions in savings Panthera identifies likely patients seven months before public sector sites start planning their recruitment campaigns. The loss of nine months patent …
